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Purpose: To compare the efficacy and tolerability of a fixed-dose combination of 0.3% 
gatifloxacin and 1% prednisolone formulation versus the same agents administered separately 
for prophylaxis in a laser-assisted in situ keratomileusis (LASIK) population.
Methods: In a prospective, randomized, double-masked, parallel-group study, 97 patients were 
evaluated for signs and symptoms of ocular infection or inflammation after bilateral LASIK. 
Group 1 (50 patients, 100 eyes) received a combined formulation of 0.3% gatifloxacin + 1% pred-
nisolone acetate (Zypred®) plus placebo. Group 2 (47 patients, 94 eyes) received conventional 
treatment with the same agents from separate vials. The cohorts were similar in age, sex, race, 
and refractive error. Baseline and postoperative assessments were made on surgery days -2, 1, 3, and 
15 and consisted of visual acuity; intraocular pressure; severity of inflammation of eyelids, con-
junctiva, and cornea; tearing; ocular discomfort (foreign-body sensation, itching, or photophobia); 
and ocular pain. The posterior segment was evaluated at the screening and exit visits.
Results: No ocular infection or persistent inflammation was detected in either group at any time. 
All objective and subjective criteria of efficacy were similar regardless of treatment, with no sig-
nificant differences between the groups. More patients who were dosed with the combined agent 
complained of mild ocular discomfort on day 3, but this difference had disappeared by day 15.
Conclusion: Post-LASIK topical prophylaxis with combined gatifloxacin + prednisolone eye 
drops (Zypred®) was well tolerated. This formulation appears to be therapeutically equivalent 
to conventional dosing with gatifloxacin and prednisolone from individual bottles for topical 
prophylaxis after laser refractive surgery.
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Introduction
In addition to preservative-free moisturizing eye drops to be used ad lib,1,2 laser-assisted 
in situ keratomileusis (LASIK) patients are usually prescribed antibiotic and steroid eye 
drops for the first 5–14 days after surgery in order to prevent infection and minimize 
inflammation.3–7 Compliance with prophylactic medications is critical to reducing the risk 
of serious complications that can have a devastating effect on a person’s quality of life.
Topical gatifloxacin 0.3% is a fourth-generation fluoroquinolone that has been 
shown to be useful in ocular surgical prophylaxis.7–10 Both in vivo and in vitro stud-
ies demonstrate improved potency of gatifloxacin against Gram-positive bacteria 
and similar or better potency against Gram-negative bacteria compared with third-
generation levofloxacin.11–13 A 1% prednisolone acetate suspension has been used for 
many years to control inflammation that can interfere with the healing process after 
ocular procedures.14Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
210
Campos et al
In a prospective, randomized, double-masked,   parallel-group 
comparative study, we looked at the results of prophylactic 
administration with a fixed-dose combined formulation of 
0.3% gatifloxacin + 1% prednisolone (Zypred®, Allergan, 
Irvine, CA, USA) versus conventional dosing with the sepa-
rate agents after LASIK.
Patients and methods
Out of a total of 101 consecutive patients seeking LASIK 
correction at our university-affiliated outpatient clinic, 
97 patients (194 eyes) met the protocol inclusion/exclusion 
criteria and were recruited for the study. These patients were 
randomly assigned by computer to one of two treatment 
groups. The group assignment was masked from patients as 
well as from investigators and clinic staff.
Group 1 consisted of 50 patients who received the 
combined 0.3% gatifloxacin (Zymar®, Allergan) + 1% predni-
solone acetate eye drops (Pred Forte®, Allergan) and placebo 
(inactive ingredients of the 0.3% gatifloxacin ophthalmic 
solution: edetate disodium, water, benzalkonium chloride, 
and sodium chloride). Group 2 consisted of 47 patients who 
received 0.3% gatifloxacin and 1% prednisolone acetate 
drops from separate vials. All patients received two identi-
cal bottles and were instructed to instill one drop from each 
bottle in each eye four times a day, with a 5-minute wait 
between drops, beginning on the day of surgery (day 0) until 
discharged from the study (day 15).
The enrollment criteria consisted of men and women of 
any race between 18 and 60 years of age, in good   general 
health, and with either myopia of up to -8.0 diopters (D) or 
hyperopia of up to +4.0 D, with or without astigmatism of 
up to 3.0 D, and whose dilated funduscopy at the time of 
enrollment was within normal limits. Patients were excluded 
from the study if they had i) a history or evidence of current 
intraocular hypertension; ii) a history or evidence of current 
systemic disease such as diabetes mellitus, autoimmune dis-
order, or herpetic, viral, bacterial, or fungal disease; iii) used 
steroids or nonsteroidal anti-inflammatory drugs within 
14 days of enrollment; iv) had a history of ocular trauma or 
inflammatory disease; v) used ocular antimicrobial drugs 
within 30 days of enrollment; vi) participated in another 
clinical study within the 12 months prior to surgery; vii) had 
single-eye vision; viii) had decreased vision from lens 
opacities; or viiii) had known or suspected hypersensitivity 
to gatifloxacin, corticosteroids, or topical anesthetic agents. 
Pregnant or lactating women or women of childbearing age 
who were not using reliable birth control methods were also 
excluded. In addition, all women of childbearing age who 
used birth control had to have a negative pregnancy test 
before enrollment. This protocol was approved by the hospi-
tal review board. The surgical candidates were asked to stop 
wearing contact lenses for at least 2 weeks before the LASIK 
procedure and to read and sign informed consent forms.
All patients underwent simultaneous, bilateral, wavefront- 
guided LASIK by the same surgeon using the LADARVision® 
system (Alcon Laboratories, Inc., Hünenberg, Switzerland). 
Patients were evaluated 2 days before surgery (day -2) and on 
postoperative day 1, 3, and 15 for signs and symptoms of ocu-
lar inflammation or infection. Baseline values were obtained 
for visual acuity (VA), intraocular pressure (IOP), clinical 
signs of inflammation of eyelids and conjunctiva (hyperemia, 
edema, discharge, or crusting), corneal edema, and corneal 
staining. These assessments were repeated on subsequent 
clinic visits, at which time any adverse events were also 
recorded. A funduscopic examination was performed on 
entering and exiting the study. At each visit, patients’ com-
plaints of tearing, eye discomfort (foreign-body sensation, 
itching, or photophobia), and ocular pain were also collected 
and made part of the study record.
The VA was determined with an Early Treatment 
Diabetic Retinopathy Study (ETDRS) chart and expressed 
in logarithm of the minimum angle of resolution values. 
  Postoperatively, the vision was measured uncorrected. 
The IOP readings were taken with the Goldmann applana-
tion tonometer, and slit-lamp biomicroscopy and physician 
clinical impression were used to gather the observational data. 
The ocular pain scale ranged from 0 = no pain to 5 = severe 
pain as rated by the patients. The fundus was visualized with 
the ophthalmoscope.
The data were reported by number and percentage of eyes 
in each treatment group and analyzed at a 5% confidence level 
(P = 0.05) with SAS®/STAT® software (Version 9.1.3) (SAS 
Institute Inc., Cary, NC, USA) as follows: the Student’s t-test 
was applied to age, VA, and IOP; the Chi-square test was 
applied to sex, race, and refractive error; the Mann–Whitney 
test was applied to the biomicroscopy data; and Fisher’s exact 
test was used to analyze the patient-reported symptoms.
Results
The demographic profile of the 97 patients who par-
ticipated in this study is detailed in Table 1. All evaluable 
patients (194 eyes) remained in the study through the day 
15 exit visit. At randomization, the treatment groups were 
similar for age, sex, and race. Patients in the separate gati-
floxacin and prednisolone group included three individuals 
identified as Asian.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The distribution of refractive errors prompting LASIK 
correction was also similar between the groups (Table 2). 
There were more eyes with isolated myopia in Group 1 
(combined treatment), and overall more eyes diagnosed with 
astigmatism in Group 2 (separate treatment), but Chi-square 
analysis showed that these differences were not statistically 
significant (P = 0.2318).
Bilateral wavefront-guided LASIK was performed 
uneventfully in 97 patients (194 eyes). There were no ensu-
ing complications or other reported problems necessitating 
concurrent medications. The postoperative visual improve-
ment (Table 3) was similar regardless of drug regimen. By 
day 1, all patients had gained at least one line on the ETDRS 
chart, and their visual acuity continued to improve until they 
were discharged from the study.
IOP remained stable in all patients throughout the early 
postoperative period encompassed by this study and was 
virtually identical regardless of which eye drops were given. 
The median IOP measurement was 12.0 mm Hg in both 
groups on days 1, 3, and 15 (Table 4).
Postoperative biomicroscopy (Table 5) revealed no 
  statistical differences between treatment groups when judged 
by objective parameters of inflammation. Eyelid hyperemia 
was recorded in one eye from Group 1 on days 1 and 3 and 
in none from Group 2. By day 15, hyperemia was recorded in 
four eyes from both groups. The lid edema data were   identical 
regardless of treatment; edema was documented in one eye 
on day 3 and in two eyes on day 15 from either group.   Eyelid 
crusting was recorded preoperatively in four eyes from Group 
1 and two eyes from Group 2. It was still present on day 1 
(two and two eyes), day 3 (one and two eyes), and day 15 
(four and two eyes), respectively.
Slit-lamp assessment of the conjunctiva on day 1 showed 
mild hyperemia in seven eyes from Group 1 and in six eyes 
from Group 2. On day 3, mild hyperemia was recorded in eight 
and four eyes, respectively, and by day 15 it was documented 
Table 1 Patient demographics by treatment group (n = 97)
Group 1a  
n = 50  
No. (%)
Group 2b  
n = 47 
No. (%)
P 
Age (years) 0.3821
Mean 32.5 31.1
Median 30 29
sex 0.8637
Male 20 (40) 18 (38.3)
Female 30 (60) 29 (61.7)
race 0.0851
Caucasian 46 (92) 42 (89.4)
Mulatto 4 (8) 2 (4.3)
Asian  0 (0) 3 (6.4)
Notes: aCombined treatment with gatifloxacin + prednisolone; bseparate treatment 
with gatifloxacin and prednisolone.
Table 2 indications for laser-assisted in situ keratomileusis by 
treatment group (n = 194)
Refractive diagnosis Group 1a 
n = 100  
No. (%) 
Group 2b 
n = 94  
No. (%)
Myopia 21 (21) 12 (12.8)
Myopia + astigmatism 66 (66) 72 (76.6)
hyperopia + astigmatism 13 (13) 10 (10.6)
Notes: aCombined treatment with gatifloxacin + prednisolone; bseparate treatment 
with gatifloxacin and prednisolone.
Table 3 Pre- and postoperative visual acuity (logarithm of the 
minimum angle of resolution) over time by treatment group 
(n = 194)
Daya Group 1b 
n = 100
Group 2c 
n = 94
P
-2
Mean ± sD  -0.06 ± 0.10 -0.04 ± 0.09
Median -0.10 -0.06 0.2526
1
Mean ± sD -0.02 ± 0.12 -0.01 ± 0.14
Median 0.0 0.0 0.6783
3
Mean ± sD -0.05 ± 0.12 -0.05 ± 0.14
Median -0.05 0.0 0.9551
15
Mean ± sD -0.04 ± 0.11 -0.04 ± 0.13
Median -0.05 -0.01 0.7336
Notes: ain relation to laser-assisted in situ keratomileusis; bCombined treatment with 
gatifloxacin + prednisolone; cSeparate treatment with gatifloxacin and prednisolone. 
Abbreviation: sD, standard deviation.
Table 4 Pre- and postoperative intraocular pressure (mm hg) 
over time by treatment group (n = 194)
Daya Group 1b 
n = 100
Group 2c 
n = 94
P
-2
mean ± sD  13.5 ± 2.2 13.5 ± 2.1
median 13.5 13.0 0.9451
1
mean ± sD 12.2 ± 2.0 12.0 ± 2.1
median 12.0 12.0 0.3537
3
mean ± sD 12.3 ± 1.8 11.9 ± 2.1
median 12.0 12.0 0.1507
15
mean ± sD 12.8 ± 2.0 12.9 ± 3.6
median 12.0 12.0 0.9202
Notes: ain relation to laser-assisted in situ keratomileusis; bCombined treatment with 
gatifloxacin + prednisolone; cSeparate treatment with gatifloxacin and prednisolone. 
Abbreviation: sD, standard deviation.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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in two eyes from either treatment group. Conjunctival edema 
was absent from all eyes in Group 1 at all times and noted in 
two eyes of Group 2 at the exit visit.
Corneal edema was absent in all patients from both 
groups at the day 15 exit visit. Minimal fluorescein staining 
of the cornea was seen in eight eyes from Group 1 and in 
three eyes from Group 2 by day 1; in six and nine eyes from 
Group 1 and 2, respectively, by day 3; and in four and six eyes, 
respectively, by day 15. These differences between treatment 
groups were not statistically significant.
Table 6 lists the results of tolerability criteria for the drug 
formulations used in the study as subjectively reported by 
patients during interviews. On the first postoperative day, 
18 eyes from either group were said to have moderate tearing, 
which subsided to mild tearing in four eyes from Group 1 
and no tearing in all eyes from Group 2 on subsequent day 3 
and day 15 visits. Ocular discomfort, represented by foreign-
body sensation, itching, or photophobia, was present in 34 
and 25 eyes from the respective groups on day 1, and in 24 
and 11 eyes on day 3, respectively. The latter difference was 
statistically significant. By day 15, discomfort persisted in 
14 eyes from Group 1 and in nine eyes from Group 2.
As to ocular pain, it was rated minimal or mild in seven 
eyes from Group 1 and in eight eyes from Group 2 on the first 
postoperative day. On day 3, only two eyes from Group 1 
reported minimal pain and by day 15 it had disappeared 
altogether.
Dilated funduscopy showed normal vitreous, retina, 
macula, and choroid of all eyes at the day 15 exit visit. 
No adverse event related to the study medications was 
reported at any time.
Discussion
Despite the popularity of LASIK and its admirable safety 
record, the risk of infection, however small, is always 
present. Every effort should be made to avert an infectious 
process during any invasive procedure on the eye, but 
especially in an elective surgery like laser keratomileusis. 
That is the reason for the widespread use of prophylactic, 
wide-spectrum, topical antibiotics in this setting.
Early postoperative inflammation and problems with 
wound healing also contribute to adverse effects seen after 
LASIK.15 A not-infrequent complication of refractive surgery 
is diffuse lamellar keratitis (DLK) or sands of the Sahara 
syndrome.16–20 DLK is characterized by diffuse inflammation 
Table 5 Signs of inflammation over time by treatment group 
(n = 194)
Biomicroscopy  
findings
Dayc Group 1a 
n = 100
Group 2b 
n = 94
P
No. (%) No. (%)
eyelids
hyperemia -2 2 (2) 0 (0) 0.1692
1 1 (1) 0 (0) 0.3323
3 1 (1) 0 (0) 0.3323
15 4 (4) 4 (4.3) 0.9290
edema -2 2 (2) 0 (0) 0.1692
1 0 (0) 0 (0) –
3 1 (1) 1 (1.1) 0.9650
15 2 (2) 2 (2.1) 0.9503
Crusting -2 4 (4) 2 (2.1) 0.4527
1 2 (2) 2 (2.1) 0.9503
3 1 (1) 2 (2.1) 0.5257
15 4 (4) 2 (2.1) 0.4527
Conjunctiva
hyperemia -2 0 (0) 0 (0) –
1 7 (7) 6 (6.4) 0.8640
3 8 (8) 4 (4.3) 0.2805
15 2 (2) 2 (2.1) 0.9503
edema -2 0 (0) 0 (0) –
1 0 (0) 1 (1.1) 0.3023
3 0 (0) 0 (0) –
15 0 (0) 2 (2.1) 0.1436
Cornea
edema -2 0 (0) 0 (0) –
1 2 (2) 0 (0) 0.1692
3 1 (1) 0 (0) 0.3323
15 0 (0) 0 (0) –
stainingd -2 0 (0) 0 (0) –
1 8 (8) 3 (3.2) 0.1489
3 6 (6) 9 (9.6) 0.3528
15 4 (4) 6 (6.4) 0.4543
Notes: aCombined treatment with gatifloxacin + prednisolone; bseparate treatment 
with gatifloxacin and prednisolone; cin relation to laser-assisted in situ keratomileusis; 
dFluorescein staining was minimal in all positive cases.
Table  6  Ocular  symptoms  over  time  by  treatment  group   
(n = 194)
Patient-reported  
symptom
Dayc Group 1a 
n = 100
Group 2b 
n = 94
P
No. (%) No. (%)
Tearing -2 2 (2) 0 (0) 0.1692 
1 18 (18) 18 (19.1) 0.8374
3 4 (4) 0 (0) 0.0605
15 4 (4) 0 (0) 0.0605
Discomfortd -2 2 (2) 0 (0) 0.1692
1 34 (34) 25 (26.6) 0.2638
3 24 (24) 11 (11.7) 0.0264
15 14 (14) 9 (9.6) 0.3419
Pain -2 0 (0) 0 (0) –
1 7 (7) 8 (8.5) 0.6946
3 2 (2) 0 (0) 0.1692
15 0 (0) 0 (0) –
Notes: aCombined treatment with gatifloxacin + prednisolone; bseparate treatment 
with gatifloxacin and prednisolone; cin relation to laser-assisted in situ keratomileusis; 
dForeign-body sensation, itching, or photophobia.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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at the flap interface after lamellar corneal surgery, apparently 
of noninfectious origin. Moshirfar et al20 note a 2.66% inci-
dence of post-LASIK keratitis, with DLK being the most 
common diagnosis overall. The occurrence of noninfectious 
keratitis (2.34%) was 7.5 times greater than that of infectious 
keratitis (0.31%).20 The mechanism for DLK after LASIK has 
been shown to be disruption of the epithelial barrier integrity 
at the flap margin.16 It is therefore of the utmost importance 
to control the burgeoning inflammatory reaction on the 
corneal surface that might lead to development of DLK; for 
this, steroids are typically prescribed.21–23 In addition to their 
prophylactic effect, early diagnosis and treatment with topical 
corticosteroids can achieve complete resolution without visual 
loss even in advanced cases of DLK.24,25
Combination eye drops consisting of an antibiotic plus 
an anti-inflammatory have proved valuable in ophthalmic 
surgery. The combined formulations simplify application, 
minimize dosing errors, prevent medication washout, increase 
patient compliance with the drug regimen, and lower the pur-
chase cost to the patient.26–31 Clinical outcomes are also appar-
ently improved by using combination products. This beneficial 
effect has been ascribed to greater drug efficacy achieved 
through better patient compliance and/or less washout.31
Various fluoroquinolone plus corticosteroid topical combi-
nations have been proposed in recent years, and experimental 
as well as clinical studies of these products have shown overall 
superior results.32–35 Fourth-generation fluoroquinolones are 
the first choice for ophthalmic antimicrobial prophylaxis,11 
and topical glucocorticoids such as prednisolone acetate and 
dexamethasone reliably control inflammatory reactions on 
the ocular surface.36–39 An earlier study by Campos et al40 
evaluated the fixed-dose formulation of moxifloxacin plus 
dexamethasone for topical prophylaxis in LASIK and found 
it to be therapeutically equivalent to conventional dosing with 
the separate agents and well tolerated by patients.
The present study compared the relative efficacy and 
tolerability of two prophylactic drug regimens after LASIK: 
a combined 0.3% gatifloxacin + 1% prednisolone eye drop 
formulation and the same agents administered singly from 
separate bottles. No evidence of infection was detected in 
any eye at any time. Conjunctival hyperemia and minimal 
corneal staining were noted in the early postoperative 
period (day 1) in up to 8% of eyes from the combination 
drops group; these findings largely resolved within 2 weeks 
and were not statistically different from those recorded with 
the separate medications. Other objective signs of ocular 
surface inflammation were minimal and transient regard-
less of treatment.
LASIK, like all eye surgeries, involves controlled trauma 
to the ocular tissues followed by a period of recovery and 
healing. In this study, the subjective impression of ocular 
discomfort (foreign-body sensation, itching, or photophobia) 
was reported in more eyes from the combined gatifloxacin + 
prednisolone group than from the separate gatifloxacin and 
prednisolone group. By day 15, the sensation of discomfort 
persisted in 14 eyes from Group 1 and in nine eyes from 
Group 2, though it was ill-defined, minimal, and of no clinical 
or statistical significance. This finding remains unexplained 
except that it may reflect the cohorts’ idiosyncrasies.
There were no adverse reactions related to either drug 
regimen, and all patients appeared to tolerate the eye drops 
very well.
Conclusion
A fixed-dose formulation of gatifloxacin + prednisolone 
was found to be effective and well tolerated for topical 
prophylaxis post-LASIK. The combined antibiotic plus 
anti-inflammatory eye drop suspension was therapeutically 
equivalent to conventional therapy with individual bottles of 
gatifloxacin and prednisolone in this population.
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